Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/18/2000CN1270591A Novel compounds
10/18/2000CN1270590A Novel compounds
10/18/2000CN1270589A Epothilone derivatives
10/18/2000CN1270587A New taxane derivatives
10/18/2000CN1270585A Substituted 1,2,3,4-tetrahydronaphthalene derivatives
10/18/2000CN1270529A Pharmaceutical compositions containing plasma protein
10/18/2000CN1270528A Nootropic agent
10/18/2000CN1270527A Use of neurotoxin therapy for treatment of urologic and related disorders
10/18/2000CN1270525A Use of physiologically acceptable vanadium compounds salts and compelxes
10/18/2000CN1270524A Cationic polymers as toxin-binding agents
10/18/2000CN1270523A Compositions for lubricating and separating tissues and biological membranes
10/18/2000CN1270522A 13-Deoxyanthracycline derivatives and processes for preparing them
10/18/2000CN1270521A Oral contraceptive preparation having a first phase comprising comprising progestin/estrogen and a second phase comprising progestin
10/18/2000CN1270520A Treatment of oppositional defiant disorder
10/18/2000CN1270519A Anti-first-pass effect compounds
10/18/2000CN1270518A Therapeutic or prophylactic agent for glomerulopathy
10/18/2000CN1270517A Antimicrobials
10/18/2000CN1270516A Pharmaceutical preparation comprising colodronate as active ingredient and silicified microcrystalline cellulose as excipient
10/18/2000CN1270515A Methods and compositions for treating pulmonary disorders using optically pure(S)-salmeterol
10/18/2000CN1270514A Pharmaceutical composition for treating dymenorrhea and premature labor
10/18/2000CN1270509A Resorcinol derivatives
10/18/2000CN1270505A Hair conditioners for treating split ends
10/18/2000CN1270173A Antisense thiooligonucleotide of targeting c-raf cancer gene, medicinal composition containing same, and application in treating cancers
10/18/2000CN1270172A Preparation of d4T from 5-methyl uridine
10/18/2000CN1270169A Benzopyrane derivatives and preparation thereof
10/18/2000CN1270168A Magnolol series of compounds, synthesizing process thereof, and medicinal composition using same as active component
10/18/2000CN1270166A Derivatives of tricyclo-substituted isohydroxyloxime acid
10/18/2000CN1270163A 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof
10/18/2000CN1270162A 3-amino-3-aryl-1-alcohol derivatives and preparation and use thereof
10/18/2000CN1270160A Refined unsaturated polyfatty acid and calcium salt of unsaturated polyfatty acid as medicinal products and preparing process thereof and preparation
10/18/2000CN1270062A Glycobiazole metal salt as synergist for radiotherapy or chemicotherapy and its preparing process and application
10/18/2000CN1270053A Medicine for treating rheumatic arthritis and hyperosteogeny and preparing process thereof
10/18/2000CN1270052A Medicinal composition for relieving sexual fatigue and delaying sanility and preparing process thereof
10/18/2000CN1270038A Fumigant lotion for treating anorectal disease and preparing process thereof
10/18/2000CN1270034A application of coenzyme in histocyte chemistry and prevention and cure of radiation injury
10/18/2000CN1270033A Gel composition for treating pulmonary tuberculosis cavity difficult to cure it
10/18/2000CN1270032A Ultrasonic concentration-difference acid-alkali method for preparing doxorubicin hydrochloride lipid as injection
10/18/2000CN1270031A Oral liquid of sodium fructose-biphosphate and preparing process thereof
10/18/2000CN1270030A Process for preparing high-purity phosphatide particles directly from concentrated phosphatide
10/18/2000CN1270029A Thebaic analgesic with controllable releasement of active content
10/18/2000CN1270028A Analgesic with controlled releasement of active content
10/18/2000CN1270027A Stable aqueous solution of phthalylglutamic acidimide derivative
10/18/2000CN1270026A Controlled releasing Qumaduo preparation having stably releasing mode and preparing method thereof
10/18/2000CN1270025A Method for preparing pills containing 90 wt.% activated pharmaceutical compositions
10/18/2000CN1057534C Erythropoietin analogs
10/18/2000CN1057531C Androstanes steroids and their medicinal compositions and uses thereof
10/18/2000CN1057525C Process improvement in synthesis of N-[3-(3-cyanopyrazolo [1,5-alpha] pyrimidin-7-yl] phenyli-N-ethyl-acetamide
10/18/2000CN1057522C Naphthalene derivs. as prostaglandin I2 agonists
10/18/2000CN1057520C N, N'-substituted imidocarbonimidic diaides derivative from hydroxylamines, its medicinal composition and uses
10/18/2000CN1057461C Natural freckle-diminishing face-beautifying product and preparation method thereof
10/18/2000CN1057443C Method for preparing antiviral medicinal compositions
10/18/2000CN1057442C Preparing method for composition pharmaceutique for parenteral injection
10/17/2000US6133479 Phenylethylamine derivatives, processes for preparing them and their use as pharmaceutical compositions
10/17/2000US6133463 For use in cosmetic and dermatological compositions for treating or caring for the skin
10/17/2000US6133460 Have primary amino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen which permit binding to nucleic acid of pathogens; conditions that photoactivate these psoralens result in inactivation of pathogens which contain nucleic acid
10/17/2000US6133458 Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
10/17/2000US6133454 Method for preparing a substituted perhydroisoindole
10/17/2000US6133446 Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
10/17/2000US6133442 For the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris
10/17/2000US6133441 Production of a salt of clavulanic acid
10/17/2000US6133440 Extract includes acetylated polysaccharide having average molecular weight of 70 to 80 kilodaltons and composed of d-galactose, d-glucose, and d-mannose having primarily beta-1,4 linkages; wound healing agents
10/17/2000US6133423 Don-1 gene and polypeptides and uses therefor
10/17/2000US6133419 Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
10/17/2000US6133326 Compositions and methods for decreasing sebum production
10/17/2000US6133324 Use of perillyl alcohol in organ transplantation
10/17/2000US6133323 Process for enhancing immune response in animals using β-carotene as a dietary supplement
10/17/2000US6133322 Treating or preventing a disorder resulting from a mitochondrial dysfunction induced by an iron overload comprising administering an effective amount of an ubiquinone derivative
10/17/2000US6133321 Method for the reduction of stress in meat producing animals and meat produced from slaughtered animals treated thereby
10/17/2000US6133320 Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
10/17/2000US6133319 For treating an interleukin-8 (il-8) mediated disease by administering a phenyl urea or phenyl thiourea of given formula, such as n-cyclohexyl-n'-(2-hydroxy-4-nitrophenyl)urea
10/17/2000US6133318 Bactericidal composition for treating infectious or pathogenic bacterial diseases or conditions in warm blooded animals comprising oxalic acid and/or oxalate in amount less than lethal dosage, with carrier and diluent
10/17/2000US6133317 For treating at least one of tumors, brain tumors, cancers, and growths in warm blooded animals such as humans or pets; composition is adapted to be administered in less than a lethal dosage; adding to pet food; pills, gelcaps
10/17/2000US6133316 Nitric oxide synthetase inhibitor or nitric oxide antagonist to reduce or eliminate unwanted physiological effects encountered with the parenteral administration of particulate drugs such as contrast agents for ultrasonic imaging
10/17/2000US6133315 Administering to treat pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal; compounds such as 2-chlorobenzenesulfonic acid 3-(3-amidinopropoxy)-5-methylphenyl ester hydrochloride
10/17/2000US6133312 Orally administering a synergistic tocotrienol and ionone mixture to inhibit tumor growth
10/17/2000US6133311 Method for preventing or treating elevated blood lipid level-related diseases by administering natural phenolic compounds
10/17/2000US6133310 Mixing invermectin with water to form lotion; applying lotion daily for seven days; repeating two to four times a month for several months; and optionally repeating once a month thereafter
10/17/2000US6133309 Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists
10/17/2000US6133306 Methods of inhibiting neurodegerative diseases
10/17/2000US6133304 Treating fibrosis, ventricular dilation, and/or heart failure in a mammal by administering an antifibrotic amount of a mixture of an angiotensin-converting enzyme(ace) inhibitor and at least one matrix metalloproteinase(mmp) inhibitor
10/17/2000US6133303 Various indene derivatives, with the exception of 5-(2-imidazole-1-yl-ethoxy)indan-1-one; treating cancer and treating or preventing restenosis or atherosclerosis
10/17/2000US6133302 Kynurenine-3-hydroxylase enzyme inhibitory activity, an enzyme of the kynurenine (kyn) pathway; compounds such as 5-(3-(3-fluorophenyl)-3-oxo-propyl)-1h-tetrazole; for treatment of neuropathological processes
10/17/2000US6133301 Pharmaceuticals for the treatment of rejection reactions in organ transplantations
10/17/2000US6133299 Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
10/17/2000US6133295 Pharmaceutical composition
10/17/2000US6133293 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action; potent depressive effect on diabetic hyperglycemia; 2,4-thiazolidinediones and oxazolidinediones
10/17/2000US6133291 3-(piperidin-1-ylalkylene)imidazole derivatives; glaucoma, antiallergens; antiinflammation and hypotensive agents, sleeping disorders; hypermotility of the gastrointestinal tract, alzheimer's disease, schizophrenia and
10/17/2000US6133288 2,8-di(hydroxy)-5-((2-piperidin-1-yl)ethyoxy-1,4-phenylene)-)-5h -benzo-(e)naphtho(1,2-c)pyran; post-menopausal syndrome, osteoporosis, cardiovascular disorders; uterine fibrosis, endometriosis, and aortal smooth muscle cell proliferation
10/17/2000US6133287 Piperidine-indole compounds having 5-HT6 affinity
10/17/2000US6133286 Antagonists; antiinflammatory agents for rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders, e.g., eczema, erythema, pruritus and acne; stroke, reperfusion injury, grafting
10/17/2000US6133284 Excellent bactericidal properties and oral absorption; infections from gramnegative and -positive bacteria; intestinal absorption, metabolic stability; side effect reduction; nonphototoxicity and noncytotoxicity
10/17/2000US6133281 Prostate cancer, benign prostatic hyperplasia, bladder dysfunction in men and women, erectile dysfunction, and other urogenital disease; administering memantidine, amantidine, dextromethorphan, ketamine; n-methyl-d-aspartate antagonists
10/17/2000US6133280 Androgen synthesis inhibitors
10/17/2000US6133279 Therapeutic agents for renal diseases and organ preservatives
10/17/2000US6133278 Prevention and therapy of cachexia associated with chronic diseases such as malignant tumor, tuberculosis, diabetes, hemodyscrasia and endocrinopathy, and aids involving progressive loss of body weight, anemia, edema and anorexia
10/17/2000US6133277 Little or no vasoconstrictor activity; gastrointestinal disorders, e.g. dyspepsia, early satiety, bloating and anorexia; 1-(3-((3,4-dihydro-2h-1-benzopyran-2-yl)methyl)-amino)-propyl)-tetrahydro -2(1h)-primidinone
10/17/2000US6133276 A ligand inhibitor of a crf/crf-binding protein complex to effect increased levels of crf; 2,4-dioxo- or 2-thiocarbonyl-4-oxo-5-(hydrocarbyl(thio)carbonylaminomethyl)-6-hydroxy-hexa-hexahydropyrimidines; alzheimer's, obesity; low side effects
10/17/2000US6133274 Hydroxyl-containing bicyclic compounds
10/17/2000US6133273 Disorders associated with bone loss by increased transcription and elevation of plasma calcitonin levels including paget's disease, post menopausal osteoporosis, senile osteoporosis, and glucocorticoid-induced osteoporosis
10/17/2000US6133272 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
1 ... 6227 6228 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 ... 7860